BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
T cell receptor signaling pathway
,
Hepatitis
,
Lymphocyte
,
Pharmacogenetics
,
PDX1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
KRAS 2
Summary
General Info
Curated Studies
Most Correlated Studies
Lung cancer KRAS-mutant A549 cells treated with aurora kinase inhibitors VX680, AZD1152, and MLN8237
T-lineage acute lymphoblastic leukemia (T-ALL) xenografts treated with GDC-0941 and PD 0325901
Acute myelogenous leukemia cells expressing activated NRAS treated with RAS pathway inhibitors
Lung cancer A549 cells (KRAS mutant) after BI-2536 and fasudil combination treatment
Prostate cancer mouse models treated with different compounds
Explore Curated Studies Results
Literature
Most Relevant Literature
Nuclear localization of non-structural protein 3 (NS3) during dengue virus infection.
Sequential Phosphorylation of the Hepatitis C Virus NS5A Protein Depends on NS3-Mediated Autocleavag…
Zika virus NS4A N-Terminal region (1-48) acts as a cofactor for inducing NTPase activity of NS3 heli…
Sequential Phosphorylation of Hepatitis C Virus NS5A Protein Requires the ATP-Binding Domain of NS3 …
Crowded environment affects the activity and inhibition of the NS3/4A protease.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA
A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutan…
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ